Ix Biopharma
Ix Biopharma Ltd, headquartered in Singapore (SG), is a pioneering biopharmaceutical company specialising in the development of innovative drug delivery systems. Founded in 2008, Ix Biopharma has made significant strides in the industry, particularly with its proprietary WaferiX™ technology, which enhances the delivery of therapeutics through sublingual administration. The company focuses on pain management and other therapeutic areas, offering unique products that provide rapid onset and improved bioavailability. With a strong commitment to research and development, Ix Biopharma has positioned itself as a leader in the biopharmaceutical sector, achieving notable milestones in product development and regulatory approvals. Its dedication to advancing patient care through innovative solutions underscores its reputation as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Ix Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ix Biopharma's score of 17 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ix Biopharma's reported carbon emissions
In 2024, Ix Biopharma reported carbon emissions of approximately 949,000 kg CO2e, all of which fall under Scope 2 emissions. This marks a slight increase from 2023, where emissions were about 937,000 kg CO2e. The company has shown a reduction in emissions since 2021, when they recorded about 997,000 kg CO2e, indicating a positive trend in their environmental impact over the past few years. Despite these fluctuations, Ix Biopharma has not set specific reduction targets or initiatives as part of their climate commitments. The absence of defined reduction goals suggests that while the company is monitoring its emissions, it may not yet have formalised a comprehensive strategy to significantly lower its carbon footprint. Overall, Ix Biopharma's emissions data reflects a commitment to transparency in reporting, although further action may be necessary to align with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | 997,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ix Biopharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
